Medite Cancer Diagnostics specializes in the development, manufacture and distribution of medical laboratory instruments for pathology, histology and cytology. Medite offers consumable products and equipment in particular for Liquid Based Cytology which is the important tool in cancer screening and detection in the field of cervical, breast, lung and other cancer types.

Type
Public
HQ
Orlando, US
Founded
1998
Size (employees)
5 (est)
Medite Cancer Diagnostics was founded in 1998 and is headquartered in Orlando, US
Report incorrect company information

Medite Cancer Diagnostics Office Locations

Medite Cancer Diagnostics has an office in Orlando
Orlando, US (HQ)
4203 34th St
Show all (1)
Report incorrect company information

Medite Cancer Diagnostics Financials and Metrics

Medite Cancer Diagnostics Revenue

Embed Graph
Medite Cancer Diagnostics's revenue was reported to be $6.81 m in FY, 2017
USD

Revenue (Q1, 2018)

1.5 m

Gross profit (Q1, 2018)

335 k

Gross profit margin (Q1, 2018), %

22.3%

Net income (Q1, 2018)

(1.4 m)

EBIT (Q1, 2018)

(960 k)

Cash (31-Mar-2018)

153 k

EV

18.5 m
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Revenue

24 k9.9 m9.2 m6.8 m

Revenue growth, %

(7%)

Cost of goods sold

8 k6.1 m5.6 m6.7 m

Gross profit

16 k3.8 m3.6 m162 k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018

Revenue

3 k3.2 m2.8 m2.1 m2.7 m2.1 m2.8 m2.3 m1.9 m1.7 m1.5 m

Cost of goods sold

1.4 m1.2 m1.2 m1.5 m1.2 m1.5 m1.3 m1.2 m1.3 m1.2 m

Gross profit

3 k1.7 m1.6 m966 k1.2 m918 k1.3 m1 m680 k369 k335 k

Gross profit Margin, %

100%55%57%45%44%43%45%43%36%22%22%
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Cash

1 k587 k108 k73 k

Accounts Receivable

10 k66.7 m

Inventories

5 k3.1 m3.8 m2.4 m

Current Assets

16 k5.6 m5.3 m3.5 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018

Cash

1 k314 k215 k247 k347 k100 k145 k32 k269 k1.7 m153 k

Accounts Receivable

8 k1.6 m1.3 m672 k

Inventories

4.8 m4.9 m3.7 m4.2 m3.6 m3.9 m4.2 m3.7 m3.6 m2.7 m

Current Assets

14 k7.2 m6.8 m5.6 m6 m5.6 m5.9 m5.9 m5.4 m6.6 m3.9 m
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Net Income

(923 k)(859 k)(2.2 m)(6.8 m)

Depreciation and Amortization

74 k177 k214 k293 k

Inventories

6 k340 k(841 k)1.4 m

Accounts Payable

(94 k)(75 k)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(358 k)(50 k)(119 k)(73 k)59 k(622 k)(202 k)(306 k)(955 k)(1.4 m)

Depreciation and Amortization

71 k

Inventories

4.8 m4.9 m3.7 m4.2 m3.6 m(186 k)

Accounts Payable

399 k95 k
USDY, 2018

EV/EBIT

-19.3 x

EV/CFO

-11.3 x

Financial Leverage

2.8 x
Show all financial metrics
Report incorrect company information

Medite Cancer Diagnostics Company Life and Culture

Report incorrect company information